JPS648604B2 - - Google Patents
Info
- Publication number
- JPS648604B2 JPS648604B2 JP628781A JP628781A JPS648604B2 JP S648604 B2 JPS648604 B2 JP S648604B2 JP 628781 A JP628781 A JP 628781A JP 628781 A JP628781 A JP 628781A JP S648604 B2 JPS648604 B2 JP S648604B2
- Authority
- JP
- Japan
- Prior art keywords
- milliequivalents
- ions
- diarrhea
- cows
- solid composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 239000008247 solid mixture Substances 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- -1 organic acid ions Chemical class 0.000 claims description 2
- 229910001415 sodium ion Inorganic materials 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 description 16
- 241000283690 Bos taurus Species 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 208000005156 Dehydration Diseases 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 238000002637 fluid replacement therapy Methods 0.000 description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- 235000014380 magnesium carbonate Nutrition 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940043432 albumin tannate Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960001482 bismuth subnitrate Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- NUJGJRNETVAIRJ-UHFFFAOYSA-N octanal Chemical compound CCCCCCCC=O NUJGJRNETVAIRJ-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960000321 oxolinic acid Drugs 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000310 rehydration solution Substances 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000036435 stunted growth Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Description
【発明の詳細な説明】
本発明は家畜特に牛の下痢時における脱水症状
の治療に用いる経口補液に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to oral fluid replenishment used for the treatment of dehydration symptoms during diarrhea in livestock, particularly cattle.
牛、特に仔牛は出産後に親牛から離された場合
にそのほとんどが下痢の症状を示す。下痢の原因
は大腸菌やロータウイルスなどの微生物、輸送や
飼育環境からのストレス等が考えられる。下痢の
症状を呈した牛は当然のことながら発育が低滞す
るのみでなく、更に下痢が続いた牛は脱水症状に
陥り、ひいては斃死するものであり、下痢による
牛の斃死率は10〜30%にも及んでいる。 Most cows, especially calves, exhibit symptoms of diarrhea when separated from their parents after giving birth. Possible causes of diarrhea include microorganisms such as E. coli and rotavirus, and stress from transportation and breeding environments. Naturally, cows that exhibit symptoms of diarrhea not only have stunted growth, but cows that continue to have diarrhea become dehydrated and even die.The mortality rate for cows due to diarrhea is 10 to 30%. %.
下痢の治療としては、抗性物質、サルフア剤、
止痢剤等の薬物投与が行われているが、その効果
は決定的でなかつた。また、脱水症状を緩和する
ためにブドウ糖、グリシン、クエン酸カリウム、
リン酸二水素カリウム、炭酸水素ナトリウム、グ
ルコン酸カルシウム、塩化カリウムなどを水に溶
解して経口的に内用させることが行われており、
その場合従来の補液においては哺乳類の体液組成
に含まれていることから補液成分としてカリウム
は必須とされていた。 Treatments for diarrhea include antibiotics, sulfur drugs,
Medications such as antidiarrheal drugs have been administered, but their effectiveness has not been conclusive. In addition, glucose, glycine, potassium citrate,
Potassium dihydrogen phosphate, sodium hydrogen carbonate, calcium gluconate, potassium chloride, etc. are dissolved in water and administered orally.
In this case, in conventional fluid replacement, potassium was considered essential as a fluid replacement component since it is included in the body fluid composition of mammals.
本発明者は下痢症状を呈している牛の状態を精
査したところ多くの場合に高カリウム血症の微候
がみとめられ、これは通常の点滴用補液の場合と
異なつて経口で補液が投与される場合には下痢罹
患時にあつては腎臓によるカリウムの排泄機能が
充分でないことに起因することに着目した。従つ
て本発明による家畜用経口補液においては従来必
須と考えられていたカリウム成分を除去すること
により意外にも下痢による脱水症状の処置に極め
て優れた結果を達成しうるものである。 The present inventor carefully examined the condition of cows exhibiting diarrhea symptoms and found signs of hyperkalemia in many cases. We focused on the fact that when patients suffer from diarrhea, the kidney's ability to excrete potassium is insufficient. Therefore, in the oral replenishment solution for livestock according to the present invention, by removing the potassium component, which was conventionally thought to be essential, it is surprisingly possible to achieve extremely excellent results in the treatment of dehydration symptoms caused by diarrhea.
本発明によれば、全量1の水溶液とした場合
にブドウ糖1〜2%およびグリシン0.3〜0.5%を
含有し且つナトリウムイオン40〜100ミリ当量、
マグネシウムイオン0〜3ミリ当量、カルシウム
イオン0〜5ミリ当量、塩素イオン30〜80ミリ当
量、リン酸二水素イオン0〜10ミリ当量、炭酸水
素イオン0〜30ミリ当量および有機酸イオン20〜
25ミリ当量の各濃度を与える量の電解質を含有し
ておりしかも全体としてカリウム形成性物質不含
の経口補液調製用固体組成物が提供される。 According to the present invention, when made into an aqueous solution with a total amount of 1, it contains 1 to 2% glucose and 0.3 to 0.5% glycine, and 40 to 100 milliequivalents of sodium ions,
0-3 milliequivalents of magnesium ions, 0-5 milliequivalents of calcium ions, 30-80 milliequivalents of chloride ions, 0-10 milliequivalents of dihydrogen phosphate ions, 0-30 milliequivalents of hydrogen carbonate ions, and 20-20 milliequivalents of organic acid ions.
A solid composition for the preparation of oral fluids is provided containing an amount of electrolyte to provide a respective concentration of 25 milliequivalents, and which is entirely free of potassium-forming substances.
前記電解質は食塩、クエン酸ナトリウム、リン
酸二水素ナトリウム、グルコン酸カルシウム、乳
酸カルシウム、炭酸水素ナトリウム、炭酸マグネ
シウム等の塩から適宜に選択されうる。 The electrolyte may be appropriately selected from salts such as common salt, sodium citrate, sodium dihydrogen phosphate, calcium gluconate, calcium lactate, sodium bicarbonate, and magnesium carbonate.
本発明による好適な補液調製用固体組成物の一
例は固体分総量基準でブドウ糖60.5〜67.2%、食
塩7.9〜9.4%、クエン酸ナトリウム6.6〜7.9%、
リン酸二水素ナトリウム0〜5.2%、乳酸カルシ
ウム0〜2.6%、炭酸マグネシウム0〜0.5%、炭
酸水素ナトリウム0〜10.1%グリシン10.0〜12.1
%からなる固体組成物である。このような固体組
成物はこれを滅菌水に溶解して浸透圧300〜350ミ
リオスモル/の水溶液となした後脱水症状を呈
している家畜特に仔牛に経口で投与する。 An example of a suitable solid composition for preparing a replacement fluid according to the present invention includes, based on the total solid content, glucose 60.5-67.2%, salt 7.9-9.4%, sodium citrate 6.6-7.9%,
Sodium dihydrogen phosphate 0-5.2%, calcium lactate 0-2.6%, magnesium carbonate 0-0.5%, sodium bicarbonate 0-10.1% glycine 10.0-12.1
It is a solid composition consisting of %. Such a solid composition is dissolved in sterile water to form an aqueous solution with an osmotic pressure of 300 to 350 milliosmol/l, and then administered orally to livestock, particularly calves, exhibiting symptoms of dehydration.
本発明の補液調製用固体組成物にはオキソリン
酸、フラゾリドン、アンピシリン、コリスチンな
どの抗菌剤、次硝酸ビスマス、タンニン酸アルブ
ミンなどの収斂剤、ケイ酸アルミニウム、薬用炭
などの吸着剤、ビフイズス菌などの菌製剤を配合
することを妨げない。 The solid composition for preparing fluid replacement of the present invention includes antibacterial agents such as oxolinic acid, furazolidone, ampicillin, and colistin, astringents such as bismuth subnitrate and albumin tannate, adsorbents such as aluminum silicate and medicated charcoal, and bifidus bacteria. This does not preclude the use of bacterial preparations.
本発明の固体組成物から調製される水溶液は下
痢症状を呈している牛に1日1頭当り1000〜2000
mlを2〜4回に分けて与える。 The aqueous solution prepared from the solid composition of the present invention is administered to cows exhibiting diarrhea symptoms at a dosage of 1000 to 2000 per cow per day.
ml divided into 2 to 4 doses.
以上詳細に述べたように本発明の補液剤水溶液
を下痢中の牛に投与した場合は、脱水症状を緩和
するのを始め、カリウム形成性物質を含まないた
めに高カリウム血症に陥ることもなく腸管の安静
を高度に保つための水分の補給が可能となり、ひ
いては下痢の治療を促進させることができるもの
である。 As described in detail above, when the aqueous solution of the fluid replenisher of the present invention is administered to cows suffering from diarrhea, it not only alleviates dehydration symptoms, but also causes hyperkalemia because it does not contain potassium-forming substances. This makes it possible to replenish fluids to keep the intestinal tract at a high level of rest, thereby promoting the treatment of diarrhea.
実施例
ブドウ糖10.00g、グリシン1.50g、食塩1.17
g、クエン酸ナトリウム0.98g、リン酸二水素ナ
トリウム0.78g、乳酸カルシウム0.38gおよび炭
酸マグネシウム0.07gを混合して経口補液調製用
固体組成物を得る。この組成物14.88gを500mlの
温湯に溶解して経口補液を得る。Example Glucose 10.00g, Glycine 1.50g, Salt 1.17
g, 0.98 g of sodium citrate, 0.78 g of sodium dihydrogen phosphate, 0.38 g of calcium lactate, and 0.07 g of magnesium carbonate to obtain a solid composition for preparing an oral replenishment fluid. Oral rehydration is obtained by dissolving 14.88 g of this composition in 500 ml of warm water.
この補液を10〜15日令の下痢症状を呈している
ホルスタイン雄仔牛10頭に、1頭当り500mlを1
日2回与えたところ2〜4日で全牛が治癒した。
これら10頭のいずれにも不整脈の発生はみとめら
れなかつた。 Apply this fluid to 10 male Holstein calves that are 10 to 15 days old and exhibiting symptoms of diarrhea.
When given twice a day, all the cows were cured within 2 to 4 days.
No arrhythmia was observed in any of these 10 animals.
一方、前記経口補液調製用固体組成物のうち、
食塩を0.88gとし、代わりに塩化カリウム0.75g
を加えたもの15.34gを500mlの温湯に溶解して経
口補液とし、この補液を前記と同様の仔牛に同様
量与えたところ、10頭のうち2頭はそのまま下痢
症状の好転をみることがなく斃死し、残り8頭は
一応治癒したがそのうち2頭が徐脈(重度の不整
脈)を示した。なお、生存牛の下痢治癒所要日数
は3〜5日であつた。 On the other hand, among the solid compositions for oral replenishment preparation,
Substitute 0.88g of table salt with 0.75g of potassium chloride.
When we dissolved 15.34g of the supplement in 500ml of warm water to make an oral rehydration solution, and gave the same amount of this replenishment fluid to the same calves as above, 2 out of 10 did not see any improvement in their diarrhea symptoms. The remaining eight dogs died, and although the remaining eight had recovered, two of them showed bradycardia (severe arrhythmia). In addition, the number of days required for the diarrhea to heal in surviving cows was 3 to 5 days.
Claims (1)
2%およびグリシン0.3〜0.5%を含有し且つナト
リウムイオン40〜100ミリ当量、マグネシウムイ
オン0〜3ミリ当量、カルシウムイオン0〜5ミ
リ当量、塩素イオン30〜80ミリ当量、リン酸二水
素イオン0〜10ミリ当量、炭酸水素イオン0〜30
ミリ当量および有機酸イオン20〜25ミリ当量の各
濃度を与える電解質を含有するがカリウムイオン
形成性物質を含有しない、家畜のための経口補液
調製用固体組成物。1 Glucose 1 to 1 when made into an aqueous solution with a total volume of 1
2% and glycine 0.3-0.5%, and contains 40-100 milliequivalents of sodium ions, 0-3 milliequivalents of magnesium ions, 0-5 milliequivalents of calcium ions, 30-80 milliequivalents of chloride ions, and 0 milliequivalents of dihydrogen phosphate ions. ~10 meq, bicarbonate ion 0-30
A solid composition for the preparation of oral fluid replenishment for livestock, containing an electrolyte giving concentrations of 20 to 25 milliequivalents and organic acid ions, but not containing potassium ion-forming substances.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP628781A JPS57120517A (en) | 1981-01-21 | 1981-01-21 | Composition for preparing oral supplementary solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP628781A JPS57120517A (en) | 1981-01-21 | 1981-01-21 | Composition for preparing oral supplementary solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57120517A JPS57120517A (en) | 1982-07-27 |
JPS648604B2 true JPS648604B2 (en) | 1989-02-14 |
Family
ID=11634168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP628781A Granted JPS57120517A (en) | 1981-01-21 | 1981-01-21 | Composition for preparing oral supplementary solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS57120517A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8528307D0 (en) * | 1985-11-18 | 1985-12-24 | Beecham Group Plc | Veterinary compositions |
JP2002308783A (en) * | 2001-04-13 | 2002-10-23 | Geo Co Ltd | Medicinal composition for preventing and treating skin or mucous membrane disease |
JP4811576B2 (en) * | 2005-03-31 | 2011-11-09 | 味の素株式会社 | Moisture electrolyte supplement drink |
-
1981
- 1981-01-21 JP JP628781A patent/JPS57120517A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS57120517A (en) | 1982-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goff et al. | Field trials of an oral calcium propionate paste as an aid to prevent milk fever in periparturient dairy cows | |
Holmberg et al. | Congenital chloride diarrhoea. Clinical analysis of 21 Finnish patients. | |
EP0226332B1 (en) | Veterinary compositions | |
Pavelić et al. | Medical applications of zeolites | |
US5028437A (en) | Treatment of animal diarrhoea | |
US5164192A (en) | Effervescent composition for oral rehydration | |
WO2002062356A2 (en) | Monovalent-selective cation exchangers as oral sorbent therapy | |
US4839347A (en) | Composition for treating dehydration | |
Laragh et al. | Effect of administration of potassium chloride on serum sodium and potassium concentration | |
Naylor | Oral fluid therapy in neonatal ruminants and swine | |
Friedman | Bowel as a kidney substitute in renal failure | |
JPS648604B2 (en) | ||
JP4428553B2 (en) | Prophylactic and / or therapeutic agent for domestic animals | |
RU2553360C2 (en) | Composition for stimulation of energy metabolic processes and method of prevention of patrimonial pathologies and postnatal diseases of cows | |
US20110293749A1 (en) | Surgical Adjuvant Composition and Associated Methods of Use | |
Islam | Citrate can effectively replace bicarbonate in oral rehydration salts for cholera and infantile diarrhoea. | |
JP4087929B2 (en) | Composition for treating chronic renal failure in cats and method for treating the same | |
EP0059057A1 (en) | Treatment of diarrhoea | |
US3055805A (en) | Process of treating acidosis with t.h.a.m. | |
RU2791325C1 (en) | Therapeutic and preventive agent for farm animals | |
WO1996037206A1 (en) | Rice flour based oral rehydration compositions for farm animals | |
JPS62126130A (en) | Medicinal composition for animals | |
RU2075972C1 (en) | Agent for treatment of young agriculture animals with gastroenteric diseases | |
RU2229887C2 (en) | Method for decreasing blood and milk nickel level in cows of technogenic area | |
RU2190413C2 (en) | Method for correcting metabolic disorders in children with dismetabolic nephropathies |